Insights into RNA Biology from an Atlas of Mammalian mRNA-Binding Proteins  by Castello, Alfredo et al.
ResourceInsights into RNA Biology
from an Atlas of Mammalian
mRNA-Binding Proteins
Alfredo Castello,1,4 Bernd Fischer,1,4 Katrin Eichelbaum,1 Rastislav Horos,1 Benedikt M. Beckmann,1 Claudia Strein,1
Norman E. Davey,1 David T. Humphreys,2 Thomas Preiss,2,3 Lars M. Steinmetz,1 Jeroen Krijgsveld,1,*
and Matthias W. Hentze1,2,*
1European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, Heidelberg 69117, Germany
2Molecular Genetics Division, Victor Chang Cardiac Research Institute, Sydney NSW 2010, Australia
3Genome Biology Department, The John Curtin School of Medical Research, The Australian National University, Building 131, Garran Road,
Acton ACT 0200, Australia
4These authors contributed equally to this work
*Correspondence: jeroen.krijgsveld@embl.de (J.K.), hentze@embl.de (M.W.H.)
DOI 10.1016/j.cell.2012.04.031SUMMARY
RNA-binding proteins (RBPs) determine RNA fate
from synthesis to decay. Employing two comple-
mentary protocols for covalent UV crosslinking of
RBPs to RNA, we describe a systematic, unbiased,
and comprehensive approach, termed ‘‘interactome
capture,’’ to define themRNA interactome of prolifer-
ating human HeLa cells. We identify 860 proteins that
qualify as RBPs by biochemical and statistical
criteria, adding more than 300 RBPs to those previ-
ously known and shedding light on RBPs in disease,
RNA-binding enzymes of intermediary metabolism,
RNA-binding kinases, and RNA-binding architec-
tures. Unexpectedly, we find that many proteins of
the HeLa mRNA interactome are highly intrinsically
disordered and enriched in short repetitive amino
acid motifs. Interactome capture is broadly appli-
cable to study mRNA interactome composition and
dynamics in varied biological settings.INTRODUCTION
RNA biology is orchestrated by the interplay of RNAs with RNA-
binding proteins (RBPs) within dynamic ribonucleoproteins
(RNPs) (Glisovic et al., 2008). Both the RBP repertoire and RBP
activities of cells respond to a multitude of biological cues and
environmental stimuli. Against this background, it is unsurprising
that numerous diseases have been linked to defects in RBP
expression and function, including neuropathies, muscular atro-
phies, metabolic disorders, and cancer (Cooper et al., 2009; Dar-
nell, 2010; Lukong et al., 2008).
Intensive efforts have been undertaken to better understand
RBPs, and much of our current knowledge of RNA-protein inter-
actions has been accumulated stepwise for more than 20 years.
Many RBPs interact with messenger RNAs (mRNAs) via a limitedset of modular RNA-binding domains (RBDs), including the
RNA recognition motif (RRM), heterogeneous nuclear RNP
K-homology domain (KH), zinc fingers (Znf), etc. (Lunde et al.,
2007). These motifs have informed in silico algorithms to identify
other proteins harboring similar signatures as putative additional
RBPs (Anantharaman et al., 2002). However, numerous nonca-
nonical RBDs have been reported (Lee andHong, 2004; Niessing
et al., 2004; Rammelt et al., 2011; Zalfa et al., 2005), reflecting
limitations in the scope of computational predictions. More
recently, systematic experimental protocols for the identification
and characterization of RBPs have been developed. Two studies
using protein microarrays and RNA probes identified about 200
RBPs from budding yeast, including several novel candidates
(Scherrer et al., 2010; Tsvetanova et al., 2010). In an alternative
in vitro approach, stable isotope labeling by amino acids in cell
culture (SILAC) and mass spectrometry (MS) were used to iden-
tify the association of polypeptides with immobilized RNA
probes (Butter et al., 2009). The most abundant proteins
captured by this assay matched bona fide RBPs that are known
to bind to the respective RNA elements. However, this approach
does not discriminate direct RNA-protein interactions from indi-
rect protein-protein interactions with RBPs; moreover, bona fide
RBPs cannot be distinguished from nonphysiological RNA
binding. Thus, comprehensive in vivo mRNA interactomes
have remained elusive.
To covalently couple proteins directly bound to RNA in vivo,
UV light of 254 nm can be used to crosslink the naturally photo-
reactive nucleotide bases, especially pyrimidines, and specific
amino acids (Phe, Trp, Tyr, Cys, and Lys) (Brimacombe et al.,
1988; Hockensmith et al., 1986). Recently, photoactivatable-
ribonucleoside-enhanced crosslinking (PAR-CL) has been
popularized. The photoactivatable nucleotide 4-thiouridine
(4SU) is taken up by cultured cells and incorporated into nascent
RNAs, and efficient crosslinking is induced by 365 nm UV light
irradiation (Hafner et al., 2010). UV crosslinking requires direct
contact (‘‘zero’’ distance) between protein and RNA and does
not promote protein-protein crosslinking (Greenberg, 1979;
Pashev et al., 1991; Suchanek et al., 2005). Both conventionalCell 149, 1393–1406, June 8, 2012 ª2012 Elsevier Inc. 1393
UV crosslinking (cCL) and PAR-CL have been used for the deter-
mination of RNAs bound by particular RBPs (Hafner et al., 2010;
Licatalosi et al., 2008).
Because the crosslinking chemistries of cCL and PAR-CL are
distinct (Greenberg, 1979; Wetzel and So¨ll, 1977), we used both
techniques in parallel to determine ‘‘all’’ RBPs bound to polyade-
nylated RNA in HeLa cells, advancing work that started with
heterogeneous nuclear ribonucleoproteins (hnRNPs) in the
1980s (Dreyfuss et al., 1984). We show that the in vivo HeLa
mRNA interactome includes hundreds of proteins that were
previously unknown to bind RNA, and we discuss resulting
insights into RNA biology.
RESULTS AND DISCUSSION
In Vivo Capture of HeLa RBPs
To determine the repertoire of proteins that directly bind to
mRNAs in living HeLa cells, we ‘‘froze’’ protein-mRNA interac-
tions by covalent UV crosslinking. Taking advantage of the
complementary crosslinking chemistries of cCL (254 nm) and
PAR-CL (4SU/365 nm), we employed both techniques in parallel.
RBPs covalently bound to polyadenylated RNAs in vivo are
captured on oligo(dT) magnetic beads following cell lysis. Unlike
strategies based on antibodies or protein tags, nucleic acid
hybridization allows the use of highly stringent biochemical
conditions tominimize contaminations, including 500mM lithium
chloride and lithium dodecyl sulfate (LiDS; 0.5%). Following
stringent washes, proteins are released by RNase treatment
and are identified using MS (Figure 1A).
With this protocol, which we term ‘‘interactome capture,’’
mRNAs are enriched over 18S ribosomal RNA (rRNA), accompa-
nied by a substantial decrease in total RNA levels after oligo(dT)
pull-down (Figures 1B and S1A available online). The b-actin,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and thy-
midylate synthase (TS) mRNAs are efficiently isolated (recov-
ering 25%–70% of the starting material) following both cCL or
PAR-CL. Enrichment of mRNAs over rRNAs was independently
confirmed by using a Bioanalyzer Chip (Figure S1B). DNA does
not copurify because no PCR amplification occurred when
samples were RNase treated before the oligo(dT) pull-down (Fig-
ure 1B) or when reverse transcriptase (RT) was omitted from the
RT reaction during complementary DNA (cDNA) preparation
(data not shown). RNA isolated by oligo(dT) purification was
also analyzed by next-generation sequencing. As expected,
mRNA was the predominant RNA population, followed by
a residual pool of rRNA and mitochondrial rRNA (Figure 1C).
Other RNAs were of low abundance or were not detected.
We next analyzed the proteins isolated by interactome
capture. Gel electrophoresis, combined with silver staining,
reveals complex protein patterns from either of the two UV-
crosslinking methods, whereas control reactions from nonirradi-
ated cells or mock pull-downs with control beads lacking
oligo(dT) were remarkably clean (Figures 1D and S1C). Both
the cCL and PAR-CL protocols recover similar RBP patterns
with some notable differences. Importantly, the patterns of iso-
lated proteins differ profoundly from the whole HeLa proteome,
indicating that interactome capture can successfully select
against abundant cellular proteins. Used as a positive control,1394 Cell 149, 1393–1406, June 8, 2012 ª2012 Elsevier Inc.the polypyrimidine tract-binding protein 1 (PTBP1), a well-known
RBP, was strongly enriched by both cCL and PAR-CL and was
undetectable in the negative control samples (Figure 1E). Like-
wise, cytosine-uracil-guanine (CUG) triplet repeat RNA-binding
protein 1 (CELF1) was isolated by both crosslinking methods;
however, cCL captured this protein more effectively, exempli-
fying an RBP that is favored by one crosslinking chemistry
compared to the other. Most importantly, negative controls for
the abundant a-tubulin, b-actin, and DNA-binding histones H3
and H4 confirm the high selectivity and specificity of the
protocol.
Proteomic Determination of the HeLa mRNA
Interactome
Following release by RNase treatment, proteins were cleaved
into peptides with trypsin. To maximize protein identification,
sample complexity was reduced by peptide fractionation using
isoelectric focusing. The resulting fractions were analyzed by
high-resolution nano-LC-MS/MS. By combining the data from
cCL and PAR-CL, we identified 1,651 proteins in the
UV-crosslinked samples, whereas only 434 proteins were identi-
fied in controls, including 335 proteins that were also found in
the collective set of proteins identified in the UV-crosslinking
samples (Figure 2A and Table S1). Therefore, 1,316 proteins
were exclusively identified by interactome capture. The overlap
of proteins identified by cCL and PAR-CL was approximately
two-thirds (64%) (Figure 2B). Although both UV-crosslinking
protocols yield comparably high numbers of proteins, 24% of
the identified proteins were found exclusively in cCL samples,
compared with 12% for PAR-CL; these data correlate well with
the protein patterns shown in Figures 1D and S1C. From a total
of 4,797 proteins detected in the HeLa whole-cell lysate (Table
S1), 1,361 were also present in the crosslinked samples after
oligo(dT) pull-down (Table S1), whereas 290 were exclusively
found in samples after interactome capture (Figure S2A).
To apply statistical data analysis, protein enrichment in cross-
linked samples over controls was assessed by two label-free
quantification methods that use different information available
from tandem mass spectrometry. The spectral count method
estimates differential protein abundance by comparing the
number of peptide identifications for each protein. Taking the
natural variation between biological replicates into account,
the bioconductor package DESeq (Anders and Huber, 2010)
provides a statistical test for assessment of differential abun-
dance of count data.
The ion count method was applied as a second quantification
approach. Ion chromatograms for each peptide were extracted
and used to quantify the relative amount of peptide ions between
one crosslinking and one negative control experiment. Taking
biological variance into account, a moderated t test imple-
mented in the software limma (Smyth, 2004) was used to detect
enriched proteins.
We determined significant enrichment of spectral counts and
ion counts for a large number of proteins (Figures 2C, 2D, S2B,
and S2C). In addition, biological replicates that were analyzed
by both statistical methods showed a strong correlation, even
for the comparison between PAR-CL and cCL (Figures 2D,
S2B, and S2C). The number of significantly enriched proteins
Figure 1. In Vivo Capture of HeLa RBPs
(A) mRNA-protein interactions are preserved by employing either UV cCL or PAR-CL protocols on proliferating HeLa cells. mRNA-protein complexes are isolated
by pull-down with oligo(dT) magnetic beads and stringently washed, and then bound proteins are eluted with RNase and identified by MS.
(B) After applying either cCL or PAR-CL, poly(A)+ RNAs were selected as in (A). As controls, beads lacking oligo(dT) (beads), RNase T1- and A-treated lysates
(RNase), or nonirradiated cells (noCL) were used. Levels of 18S rRNA, b-actin, GAPDH, and TS mRNAs in samples were monitored by RT-qPCR. SDs were
calculated from four biological replicates.
(C) RNAs isolated following cCL or noCL protocols were analyzed by sequencing, and the relative amounts of different RNAs are plotted.
(D–E) Samples were digested with RNases, and released proteins were analyzed by silver staining (D) and western blotting against PTBP1, CUG-BP, a-tubulin,
b-actin, and histones (H)3 and H4 (E).
See also Figure S1.was 493 from the spectral count method and 797 from the more
sensitive ion count method (false discovery rate 0.01 in both
cases) (Figure 2E). Combining the two analyses, 860 proteinswere enriched after UV crosslinking by at least one of the two
quantification methods. Because these 860 proteins qualify as
RBPs according to stringent biochemical and statistical criteria,Cell 149, 1393–1406, June 8, 2012 ª2012 Elsevier Inc. 1395
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Figure 2. Proteomic Analysis of HeLa
mRBPs
Poly(A)+ RNAs were isolated as in Figure 1A. Three
experimental (two cCL and one PAR-CL) and three
control (two noCL and one 4SU noCL) biological
replicates were processed by MS.
(A) Venn diagram comparing the number of
proteins identified in the three crosslinking (CL)
experiments (pink) or in their respective controls
(blue).
(B) Percentage of proteins identified in one cCL
(pink) or in one PAR-CL experiment (blue).
(C) Scatter plot of spectral counts comparing
a cCL experiment to a control experiment. Each
dot represents one protein. Axes depict the
number of unique peptide identifications. Proteins
in red are significantly enriched according to the
DESeq method.
(D) Scatter plot comparing the differential ion
counts of two biological replicates. Axes show the
log2-fold change in ion counts between cCL and
noCL. Proteins significantly enriched according to
the ion-count method in cCL or control experi-
ments are depicted by red or blue dots, respec-
tively.
(E and F) Venn diagrams comparing the number of
proteins (E) quantitatively enriched by the spectral
count method (pink) or by the ion-count method
(blue) or (F) quantitatively enriched in crosslinking
experiments compared to controls (HeLa mRNA
interactome, pink); total number of proteins iden-
tified in crosslinking experiments (blue).
(G) Density of the calculated isoelectric points (pI)
of all human proteins (red), HeLa whole-cell lysate
(blue), HeLa mRNA interactome (green), and
proteins annotated as RNA binding (purple).
(H) Density of hydrophobicity for the same protein
groups as in (G).
See also Figures S2 and S3 and Tables S1 and S3.we refer to them as the ‘‘HeLa mRNA interactome’’ (Figure 2F).
Note that 14 of these proteins are listed as ‘‘enriched,’’ but not
as ‘‘identified,’’ because their corresponding peptides were not
identified in crosslinked samples with false discovery rate
(FDR) <0.01; however, they reached this identification threshold
by taking into consideration data from the control experiments.1396 Cell 149, 1393–1406, June 8, 2012 ª2012 Elsevier Inc.Although the quantitative value extracted
for these peptides is significantly larger
in crosslinked samples than in controls
(FDR < 0.01), qualifying their inclusion in
the mRNA interactome, these 14 pro-
teins should nonetheless be considered
against this background and are indi-
cated in Table S1 (red font).
Earlier analyses of complex pro-
teomes, for example from C. elegans
or D. melanogaster, noticed a technical
bias of MS regarding protein abun-
dance, isoelectric point (pI), hydropho-
bicity, and protein size (Brunner et al.,2007; Schrimpf et al., 2009). Compared to proteins predicted
from the human genome, basic, hydrophobic, and low abun-
dance proteins are underrepresented in the HeLa whole-cell
lysate (Figures 2G, 2H, and S2D; red versus blue line);
however, protein size did not substantially affect protein iden-
tification (Figure S2E). In contrast to the whole-cell lysate,
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Figure 3. Experimental Validation of the HeLa mRNA Interactome
(A) Scheme of the dual fluorescence validation method.
(B) Classification of the identified proteins.
(C) Relative TRed/EGFP fluorescence ratios from controls and candidate EGFP/YFP-tagged proteins after normalization to the ratio of unfused EGFP. Error bars
represent SDs from nine independent IPs (three biological replicates). *p < 0.05 and **p < 0.01 after t test.
(D and E) RNAs crosslinked to and coimmunoprecipitated with YFP/EGFP-taggedMOV10, NXF1, ENO1, and SHMT2 were analyzed by sequencing. (D) Number
of genes significantly enriched (p < 0.05) over control samples (RNAs coimmunoprecipitated with EGFP). (E) Heatmap showing themRNAs bound to each protein
(p < 0.05).
See also Figure S3 and Tables S2 and S7.basic proteins were more prevalent in the HeLa mRNA
interactome than acidic ones, as seen for proteins annotated
by the gene ontology (GO) term ‘‘RNA-binding’’ (Figure 2G,
green versus purple line). Moreover, these latter protein sets
showed similar densities for hydrophobicity and mRNA abun-
dance (Figures 2H and S2D). Therefore, the HeLa mRNA
interactome displays the expected chemical and biological
features.Experimental Validation of the HeLa mRNA Interactome
For validation, we developed a fluorescence-based quantitative
method to monitor mRNA-protein interactions. We generated
‘‘Tet-on’’ HeLa cell lines stably expressing enhanced green fluo-
rescent protein (EGFP)/yellow fluorescent protein (YFP)-tagged
proteins (23 candidates and 6 negative controls) (Figure 3A).
Following Tet induction and UV crosslinking, EGFP/YFP
chimeric proteins were immunoprecipitated (IP) with a highCell 149, 1393–1406, June 8, 2012 ª2012 Elsevier Inc. 1397
affinity and specificity single-chain antibody from Lama paca
(Rothbauer et al., 2008). Immunoprecipitates were stringently
washed, and the presence of crosslinked polyadenylated
RNAs was revealed by hybridization of Texas red (TRed)-labeled
oligo(dT). Thus, the fluorescence ratio of TRed (RNA) over EGFP
(protein expression) serves as a quantitative measure of poly(A)
RNA binding.
All 1,651 identified proteins were ranked according to their
spectral and ion count scores. For the 860 proteins of the inter-
actome, the top 70%, next 15%, and bottom 15% were as-
signed to classes I–III, respectively (Figure 3B). The remaining
identified proteins were considered as class IV. Candidate
RBPs from classes I, III, and IV were selected, including under-
represented categories such as kinases and intermediary
metabolism enzymes (see below).
All negative controls, including three DNA-binding proteins
(RUVBL1, PCNA, and H2B), showed TRed/EGFP ratios close
to background (unfused EGFP) (Figure 3C). Conversely, nine
out of ten class I candidates display significantly higher relative
fluorescence values (Figure 3C). Seven out of nine proteins
from class III and one out of four from class IVwere also validated
by this assay. Notably, the number of validated proteins in each
class correlates well with the MS quantification data. Some of
the nonvalidated candidates could represent false negatives
because the EGFP/YFP tag may interfere with RNA binding of
some RBPs.
For an independent test of RNA binding and to obtain insights
into the spectrum of bound RNAs, we identified RNAs cross-
linked to GFP/YFP-fused MOV10, NXF1, ENO1, SHMT2, or
EGFP alone following GFP/YFP immunoprecipitation by next-
generation sequencing. After cDNA library preparation, primer
ligation, and amplification, equal amounts of DNA were sub-
jected to Sequencing by Oligonucleotide Ligation and Detection
(SOLiD); this normalization procedure overestimates RNA
binding by the negative control EGFP because a far greater
number of cell equivalents were used. As shown in Figures 3D
and S3A and Table S2, a large number of mRNAs are signifi-
cantly enriched in immunoprecipitations of RBP candidates
compared to the EGFP control. Nevertheless, a small set of
highly abundant HeLa mRNAs was prevalent in EGFP samples
(Figure S3B); these contaminants likely passed the detection
threshold due to the overrepresentation of this sample in the
sequencing runs. MOV10 and NXF1 display broad RNA binding,
whereas the enzymes ENO1 and SHMT2 bind specific and
distinct subsets of RNAs (Figure 3E). Evidently, even the class
IV candidate SHMT2 is validated by both assays, confirming
that this class harbors additional bona fide RBPs.
Technical Aspects of the Interactome Capture Protocol
To differentiate bona fide RBPs from nonspecific binders, we
applied stringent biochemical and statistical criteria. This choice
minimizes false positives but comes at the price of false nega-
tives. Their number is difficult to estimate, especially because
we presently do not know how many of the class IV proteins
represent physiological RBPs. For example, IRP1 (ACO1), the
regulatory RBP of cellular iron homeostasis, failed to be identi-
fied in the crosslinked samples, although it is detected in the
HeLa whole-cell lysate (Table S1). Such a false-negative result1398 Cell 149, 1393–1406, June 8, 2012 ª2012 Elsevier Inc.could originate from the lack of IRP1 binding to its target mRNAs
due to an iron-replete state of the cultured cells (Hentze et al.,
2010) and/or from inefficient crosslinking when bound to its
targets. Generalizing this limitation, our approach will fail to
detect physiological RBPs when: (1) they are not expressed in
HeLa cells, (2) they do not bind polyadenylated RNAs, (3) their
RNA-binding activity is inhibited in proliferating HeLa cells, or
(4) bound RBPs fail to be crosslinked by both cCL and PAR-CL.
However, most of the RRM-containing proteins (136/151, see
below), all of the hnRNPs (18/18), and almost all of the RNA
helicases (19/23) detected in the HeLa whole-cell lysate are
also found in the HeLa mRNA interactome, suggesting that it
represents a reasonably comprehensive atlas of the HeLa cell
mRNA-binding proteins.
In theory, both UV-crosslinking protocols should select for
proteins that directly bind to RNA and discriminate against those
that associate indirectly as subunits of larger RNA-binding
complexes without directly contacting the RNA because the
UV-crosslinking protocols do not mediate protein-protein cross-
linking (Greenberg, 1979; Pashev et al., 1991; Suchanek et al.,
2005) and because the purification conditions (0.5 M LiCl;
0.5% LiDS) will dissociate most noncovalent protein-protein
interactions. The core exon junction complex represents
a high-affinity heterotetramer composed of eIF4AIII (EIF4A3),
Y14 (RBM8A), MAGOH, and Barentz (CASC3, BTZ), whose coc-
rystal structure with RNA is known (Figure 4A) (Bono et al., 2006).
Consistent with the structural information and supporting
the selectivity of interactome capture, we find eIF4AIII and
CASC3 to be components of the mRNA interactome, whereas
Y14 and MAGOH are absent (Table S1). Although we consider
the mRNA interactome as being validated as a complex data
set, each individual member of it should be considered as
a high-probability RBP, recommended for individual validation
by researchers planning to explore these proteins’ functions in
RNA biology in greater depth.
cCL versus PAR-CL
The two-pronged approach with cCL and PAR-CL offers advan-
tages over the use of a single method because the majority
of RBPs of the interactome are independently confirmed by
a second protocol. Whereas most of the proteins are similarly
captured by the two techniques, for a few dozen proteins, cCL
or PAR-CL showed superior performance compared to the
other, providing technically useful information (Figures S3C
and S3D and Table S3). For example, CELF1 is more efficiently
captured by cCL than PAR-CL, in agreement with Figure 1E (Fig-
ure S3C); the converse applies to the Y-box-binding protein 1
(YBX1).
PAR-CL has recently been popularized as being more efficient
than cCL in protein-RNA crosslinking (Hafner et al., 2010). About
12% of the interactome was captured solely by PAR-CL (Fig-
ure 2B), but twice as many RBPs (24% of the interactome)
were identified only by cCL and could have been missed if
PAR-CL had been used alone.
Known and Previously Unknown RBPs
To benchmark the HeLa mRNA interactome against known
RBPs, we carried out a gene set enrichment analysis assessing
functional and structural properties using gene ontology. As
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Figure 4. Analysis of the HeLa mRNA Interactome
(A) Ribbon diagram of the crystal structure of the core exon junction complex
consisting of eIF4AIII, Magoh, Y14 (residues 66–174), and CASC3 (residues
137–286), associated with U15 RNA at 2.2 A˚ resolution (PDB 2J0Q) (Bono et al.,
2006). EIF4A3 (eIF4AIII, red) and CASC3 (green) contact the RNA directly
(yellow), which is in contrast to Y14 (light gray) and Magoh (dark gray). Amino
acids from eIF4AIII and CASC3 in contact with the RNA are shown in dark blue
and cyan, respectively.predicted, RNA-binding annotations far exceed DNA binding in
the HeLa mRNA interactome (Figure S4A), with RNA binding it-
self being the most enriched GO term, followed by more defined
RNA-binding activities such as mRNA binding (Figure 4B and
Table S4). In addition, other RNA biology-related functions
and processes are highly represented, e.g., protein synthesis
and RNA metabolism (Figures S4B–S4E). Kinases, phospha-
tases, receptors, transporters, proteins involved in mitosis,
DNA synthesis, and intermediary metabolism are statistically
underrepresented (Figures 4B and S4B–S4E and Table S4);
some RBPs from these underrepresented categories will be dis-
cussed in greater detail below.
To estimate the number of ‘‘previously unknown’’ RBPs, we
assembled a catalog of experimentally validated RBPs and
compared it with the HeLa mRNA interactome and the GO anno-
tation ‘‘RNA binding’’ in ENSEMBL (Figures 4C and 4D). Because
some well-known RBPs are not annotated as RNA binding in
public databases, we further removed proteins with GO annota-
tions related to RNA (e.g., RNAmetabolism). Even after this strin-
gent counterselection, the HeLa mRNA interactome adds 315
high-probability RBPs to those identified in the past decades
(Figure 4D). In addition, the HeLa mRNA interactome provides
direct experimental support for RNA binding of a large number
of proteins (222) that, in spite of being annotated in GO as RNA
binders, had only been inferred to represent RBPs by homology.
Insights into Modes of RNA Binding
Globular Domains
About half of the mRNA interactome proteins harbor known
RBDs, and as a consequence, several classical (e.g., RRM,
KH, and DEAD box helicase) and nonclassical (e.g., LSM and
YTH) RBDs are statistically overrepresented (Figures 5A–5C).
Dual-specificity domain families with sparse evidence for RNA
binding were also present in our data set (Figure 5C). For
example, the SAF-A/B, Acinus, and PIAS (SAP) domain (Figures
S5A and S5B) is commonly associated with DNA binding;
however, in the exonuclease ERI1, it has been shown to interact
with the 30 end stem loop of histone mRNA (Yang et al., 2006)
(Y. Cheng and D.J. Patel, personal communication; PDB
1ZBH) (Figure S5C). Our data support a broader role of SAP
domains in RNA binding because most of the SAP-domain-
containing proteins identified in the HeLa whole-cell lysate are
also found in the HeLa mRNA interactome (12/14), and eight of
these do not harbor a canonical RBD.
Another example is tryptophan-aspartic acid 40 (WD40),
which consists of repeats of a 31–60 residue-conserved motif
(WD40 motif) that forms b-propeller structures known as WD
domains (Figure S5D). This protein architecture generates an
excellent platform for the evolution of diverse binding specific-
ities (mostly protein binding), and the domain family has(B) Ten of the most significant over- (blue) and underrepresented (pink)
molecular function GO terms of the mRNA interactome.
(C) Comparison of the mRNA interactome with the GO term ‘‘RNA binding.’’
(D) Number of experimentally validated RBPs, RBPs inferred by homology,
RBPs with the GO annotation ‘‘RNA related,’’ or RBPs without RNA-related
annotation in the mRNA interactome.
See also Figure S4 and Table S4.
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Figure 5. Globular Domains in HeLa mRNA Interactome Proteins
(A) Number of proteins harboring classical, nonclassical, or unknown RBDs in the mRNA interactome. For the purpose of this figure, we considered the RBDs
listed in Lunde et al., (2007) as classical and protein domains that have been experimentally shown to bind RNA in at least one example as nonclassical.
(B) Number of proteins annotated with each classical domain in the mRNA interactome (dark) or only identified in HeLa whole-cell lysate (light).
(C) Number of proteins annotated with each nonclassical domain. Only domains with four hits or more are shown. Proteins containing both classical and
nonclassical RBDs are listed in (B).
(D) Balloon plot cross-referencing functional (GO) and structural (Pfam domains) annotations of the proteins in the HeLa mRNA interactome.
(E) Distribution of Pfam domains in the proteins of the HeLa mRNA interactome without known RBD. Only Pfam domains with at least three hits are shown.
(F) Comparison of different Znf proteins of the mRNA interactome with the GO terms RNA binding and DNA binding.
(G) Occurrence of Znf motifs within the HeLa mRNA interactome (red) and HeLa whole-cell lysate (pink).
See also Figure S5 and Table S5.expanded significantly in higher eukaryotes (Stirnimann et al.,
2010). Interestingly, the WD domain of Gemin5 displays RNA-
binding activity (Lau et al., 2009), suggesting that WD domains
can interact, at least in some instances, with RNA. In agreement,
23 WD domain-containing proteins are found to be associated1400 Cell 149, 1393–1406, June 8, 2012 ª2012 Elsevier Inc.with poly(A)+ RNAs in HeLa cells, none of which harbor classical
RBDs. The physicochemical properties of these putative mRNA-
bindingWD domains differ fromWDdomains of proteins that are
not present in the HeLa mRNA interactome, being enriched
for most of the amino acids typically found at protein-RNA
interfaces (especially basic amino acids) (Lunde et al., 2007) (Fig-
ure S5E). Homology modeling of the WD domain of UTP15 re-
vealed clusters of basic amino acids at the surface of the
b-propeller that may serve as a platform for docking RNA
(Figure S5F).
Orphan proteins without knownRNA-bindingmotifs constitute
half of the HeLa mRNA interactome, and most of these also lack
RNA-binding or RNA-related GO annotations (Figures 5A and
5D). We searched for domains or motifs that are enriched among
these proteins, which could represent RBDs. Two domains co-
occur in all members of the poorly characterized fas-activated
serine/threonine (FAST) kinase family: the FAST kinase domain
and the RNA-binding domain abundant in Apicomplexans
(RAP) (Figures 5E and S5G). The RAP domain is a putative
RBD without supporting experimental evidence (Lee and Hong,
2004). Homologymodeling of the RAPdomain revealed an endo-
nuclease-like fold that generates an interface rich in basic and
aromatic residues that might be involved in RNA binding (Figures
S5H and S5I). We identified all (six) human RAP-domain contain-
ing proteins in crosslinked samples, including four in the HeLa in-
teractome (Table S5); two of these (FASTKD2 and FASTKD1)
were validated independently as RBPs (Figure 3C). Therefore,
FAST kinases represent a family of directly RNA-binding kinases.
Znf are classical nucleotide-binding domains that are subclas-
sified by the order of the zinc-contacting amino acids (Lunde
et al., 2007). We found 69 Znf-containing proteins within the
mRNA interactome,many of which were previously uncharacter-
ized as possessing RNA-binding activity (Figure 5F). CCCH,
CCHC, and RNPHF Znf motifs are well known to bind RNA
and, expectedly, are enriched in the mRNA interactome.
AKAP95 and HC5HC2H Znf subtypes, previously thought to
bind exclusively DNA, are also overrepresented in our data set
(Figure 5G), suggesting that they also represent bona fide
RBDs. The remaining Znf domain classes occurred more
sporadically.
Seven peptidyl-prolyl cis-trans isomerases (PPI) are found in
the interactome (Table S5). PPIs play regulatory roles in spliceo-
some and ribonucleoprotein dynamics by interconverting cis and
trans conformations of proline isomers (Mesa et al., 2008). PPIE
and PPIL4 contain one RRM (grouped with the proteins
harboring classical RBDs in Figures 5A and 5B) (Mi et al., 1996;
Zeng et al., 2001). However, five additional PPIs lacking known
RBDs are also present within the mRNA interactome (Figure 5E
and Table S5), and we validated PPIB as an RBP (Figure 3C).
PPIG and PPIA contribute to ribonucleoprotein dynamics
(Mesa et al., 2008; Pan et al., 2008), the latter being essential
for hepatitis C virus (HCV) replication (Foster et al., 2011). The
presence of several PPIs in the mRNA interactome suggests
that this protein family plays broader roles in RNA biology than
previously anticipated.
Repetitive Disordered Motifs
Large portions of the human proteome are intrinsically disor-
dered, natively lacking stable three-dimensional structure.
Disordered regions are frequently endowed with high functional
density containing multiple interaction interfaces and may be
involved in regulatory functions, including facilitation of RNA
folding as RNA chaperones (Dyson and Wright, 2005; Tompa
and Csermely, 2004). Proteins within the mRNA interactomeare highly enriched in intrinsically disordered regions compared
to the human proteome or HeLa whole-cell lysate (p = 2.2 3
1016) (Figure 6A). However, the physicochemical properties of
these unstructured segments of RBPs differ from comparable
regions of whole-cell lysate, with a prevalence of glycine (G),
arginine (R), and lysine (K) residues (Figure 6B). Unexpectedly,
tyrosine (Y) is also enriched in these segments (especially in
proteins containing classical RBDs), although the ‘‘order-
promoting’’ aromatic residues are depleted in disordered
regions of the human proteome (Figure S6A) (Radivojac et al.,
2007). Amino acids that are enriched in the unstructured regions
of the mRNA interactome are also commonly found in globular
RBDs (Lunde et al., 2007); conversely, acidic amino acids, which
are usually of low abundance in those interfaces, are underrep-
resented (Figure S6A). Another striking property of disordered
segments in RBPs is that low complexity and repetitive amino
acid sequences are overrepresented compared to similar
regions within the human proteome or HeLa whole-cell lysate
(p = 2.2 3 1016) (Figures 6C and 6D). These features apply to
RBPs lacking known RBDs and RNA-related GO annotations
(disorder, p = 3.73 106; complexity, p = 4.253 105; repetitive
sequences: p = 2.6 3 109) (Figures 6A–6D).
Several repetitive sequences in unstructured regions of RBPs
form recognizable patterns shared between evolutionarily unre-
lated proteins of the mRNA interactome (Figures 6E, S6B, and
S6C). Arginine co-occurs preferentially with serine (S) (Figure 6E),
reflecting the regulatory importance of arginine-serine (RS)
dipeptides, particularly in the serine-arginine (SR) protein family
(Twyffels et al., 2011). Arginine also combines with glycine, form-
ing the arginine-glycine-glycine (RGG) box RNA-binding motif
(Figure 6E), which binds a guanine-rich sc1 RNA sequence in
fragile X mental retardation protein 1 (FMR1) with nanomolar
affinity (Phan et al., 2011). The FMR1 segment R533GGGGR538
recognizes sc1 RNA by shape complementarity and intermolec-
ular hydrogen-bonding interactions with the Watson-Crick
bases G31 and G7 (Phan et al., 2011). RGG boxes vary in the
length and number of repeated units, and they are often found
in mRNA interactome proteins in combination with classical or
nonclassical RBDs or other repetitivemotifs as well as in proteins
lacking known RNA-binding architectures (Figures 6F, 6G, and
S6D). This suggests that RGG boxes are broadly used platforms
for RNA binding, which could contribute cooperatively to the
modular design of RBPs by increasing the affinity and the spec-
ificity of the protein-RNA interaction. In some instances, glycine
also combines with tyrosine, forming tyrosine-glycine-glycine
(YGG) boxes (Figure 6E). The function of this motif is unknown;
nevertheless, we find it frequently in combination with RBDs or
RGG boxes (Figures 6F, 6G, and S6D). YGG boxes could employ
a similar mechanism of RNA binding as RGG boxes by using the
tyrosine side chain to interact with RNA bases by stacking or
hydrogen bonding.
Basic disordered tails are often used by transcription factors
to bind DNA (Vuzman and Levy, 2012). In this regard, lysine-
rich segments are also found in mRNA interactome proteins,
and they are especially abundant among the previously unknown
RBPs (Figures 6E–6G). In some cases, poly(K) motifs coincide
with experimentally validated nuclear localization signals (NLS);
however, they are frequently longer than the classical NLSCell 149, 1393–1406, June 8, 2012 ª2012 Elsevier Inc. 1401
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Figure 6. Repetitive Motifs in HeLa mRNA Interactome Proteins
(A) Distribution of calculated disorder regions of all human proteins (red), HeLa whole-cell lysate (blue), mRNA interactome (green), and proteins lacking known
RBDs (purple).
(B) Enrichment of amino acids in disordered regions of the mRNA interactome.
(C and D) Distribution of calculated low-complexity regions (C) and repetitive dipeptide sequences (D) for the same protein groups as in (A).
(E)Sequence logosofaminoacidsaroundrepetitive residues.Apositionweightmatrix iscomputed fromall 11-mersequencesaroundall residues in repetitive regions.
Sequence logos are shown for the central amino acids R, Y, or K. The height of the letters is proportional to the probability of amino acid occurrence at each position.
(F) Occurrence of disordered repetitive motifs in mRNA interactome proteins.
(G) Schematic representation of repetitive motif distribution in proteins containing classical RBDs or lacking known RBDs.
(H) Number of proteins of the mRNA interactome listed in the OMIM database: proteins annotated in GO as RNA-binding (red), proteins not annotated as RNA
binding (blue).
See also Figure S6 and Table S6.definition and form patches with nonrandom distribution (Fig-
ure 6G). Hypothetically, poly(K) patches could establish electro-
static interactions with the phosphate backbone of RNA in
analogy with the basic tails in DNA-binding proteins (DBPs) (Vuz-
man and Levy, 2012). Length and net charge of basic tails in ho-
meodomain transcription factors influence their DNA-binding
properties (Vuzman et al., 2010; Vuzman and Levy, 2010). Poly(K)
patches in RBPs could follow similar principles for binding
affinity and specificity. Alternatively, poly(K) tracts could be
involved in interactions with acidic protein patches, which we1402 Cell 149, 1393–1406, June 8, 2012 ª2012 Elsevier Inc.also observe in HeLa RBPs (Figures 6F, 6G, S6C, and S6D), as
occurs with K-rich histone tails (McBryant et al., 2010).
The presence of repetitive motifs within disordered regions
and their conservation in nonhomologous RBPs point toward
an emerging role of such intrinsically disordered domains in
RNA biology.
Insights into Mendelian Disease
Eighty-six proteins of the mRNA interactome are listed in the
Online Mendelian Inheritance in Man (OMIM) database as being
associated with humanMendelian disease (ENSEMBL 63). Most
of these were previously unknown to be RBPs (Figure 6H and
Table S6). Disturbances of RNA metabolism can now be
explored for these 48 proteins to further understand their roles
in the respective human disorders. In some cases, the same
syndromes are caused by alterations of both known and previ-
ously unknown RBPs (Table S6). For instance, non-insulin-
dependent diabetes mellitus can be caused by mutations in
the well-known RBP IGF2BP2 and also by mutations in the inter-
actomeprotein PTPN1 (also called PTP1B). PTPN1 is a phospha-
tase, one of the most underrepresented functions in the mRNA
interactome (Figure 4B); it has also been implicated in cancer
(Lessard et al., 2010).
Similarly, a FASTKD2 mutation generating a premature stop
codon was identified in patients with infantile mitochondrial
encephalomyopathy associated with cytochrome c oxidase
deficiency (mitochondrial complex IV deficiency in OMIM), an
infrequent developmental disease with severe symptoms
(Ghezzi et al., 2008). This mutation generates a truncated protein
lacking part of the FAST kinase and the whole RAP domain with
decreased susceptibility to apoptotic stimuli (Figure S5G). Thus,
the role of FASTKD2 as an RBP (validated in Figure 3C) in
apoptosis and infantile mitochondrial encephalomyopathy asso-
ciated with cytochrome c oxidase deficiency calls for further
exploration.
‘‘Moonlighting’’ Enzymes and REM Networks
Cytosolic aconitase is an enzyme that plays a key physiological
role as an iron-regulated mRNA-binding protein (iron regulatory
protein 1/IRP1) (Hentze and Argos, 1991; Rouault et al., 1991).
Other enzymes of intermediary metabolism have been impli-
cated in ‘‘moonlighting’’ as RNA-binding proteins, although the
evidence supporting RNA binding in vivo is limited (Ciesla,
2006; Hentze, 1994). Using the ‘‘reactome’’ annotation (Joshi-
Tope et al., 2005), the HeLa mRNA interactome harbors 17
enzymes of intermediary metabolism, and the extended class
IV list increases this count to 46 (Table 1). In part, this list confirms
earlier experiments (Ciesla, 2006; Elzinga et al., 1993, 2000; Kiri
and Goldspink, 2002; Liu et al., 2001; Nagy and Rigby, 1995;
Nakagawa et al., 1995; Pioli et al., 2002; Shetty et al., 2004),
and it also identifies metabolic enzymes not previously known
as RBPs. We validated four of these as RBPs by the dual fluores-
cence assay (Figure 3C); ENO1 and SHMT2 were also validated
by sequencing of associated RNAs (Figures 3D and 3E).
The HeLa cell RNA-binding enzymes cover much of the land-
scape of intermediary metabolism, including carbohydrate,
amino acid, lipid, and nucleotide metabolism, and they appear
not to cluster into particular pathways. If functionally relevant,
as proposed by the REM (RNA, enzyme, and metabolite)
network hypothesis (Hentze and Preiss, 2010), these proteins
could broadly connect intermediary metabolism with RNA
biology and posttranscriptional gene regulation.
Oxidoreductase, transferase, and kinase are prevalent cata-
lytic activities among these enzymes. Six of the RNA-binding
enzymes in the mRNA interactome and, additionally, 12 in the
identification set use NAD+, NADP+, NADH, NADPH, FAD, or
FADH2 as cofactors via the dinucleotide-binding (Rossmann)
fold. The Rossmann fold constitutes an RBD for GAPDH andLDH (Nagy and Rigby, 1995; Pioli et al., 2002), but Rossmann-
fold-containing proteins are underrepresented in the HeLa inter-
actome overall (Figure S4E). Therefore, this domain does not
appear to suffice for RNA binding unless the (metabolic) state
of proliferating HeLa cells is incompatible with RNA binding by
the other Rossmann-fold-containing proteins.
Finally, five of the metabolic enzymes in the interactome and
an additional five in the identification data set share their ability
to simultaneously bind ATP and an anionic substrate such as
succinate, L-aspartate, or pyruvate. The role of this property
for RNA binding also deserves further exploration.
Outlook
The mRNA interactome capture methodology was developed
here to generate a comprehensive atlas of mRNA (strictly: poly(A)
RNA)-bindingproteinsofa livingcell. In spiteof their limitations,we
choseHeLacells for their economyandeaseof handlingaswell as
the wealth of available tools and information. We believe that this
work offers an informative snapshot of RNA biology. Interactome
capture can now be adapted to study the mRNA interactomes of
other cells and organisms. The approach can also be applied to
investigate changes in interactome composition as a function
of different biological conditions such as metabolic changes,
differences in cell growth/the cell cycle, forms of stress (hypoxia,
oxidative stress, nutrient deprivation, etc.), developmental and
differentiation stages, or the response to drugs. Applied to query
suchbiological contexts,mRNA interactomesand their responses
could offer unprecedented insights into biological states, comple-
menting analyses of transcriptomes and proteomes.
EXPERIMENTAL PROCEDURES
In Vivo Isolation of HeLa RBPs
HeLa cells were grown overnight in the presence (PAR-CL) or absence (cCL) of
4-thiouridine. Cells were irradiated with UV light at 254 nm (for cCL) or 365 nm
(for PAR-CL), harvested, and lysed. Poly(A)+ mRNAs and crosslinked proteins
were captured with oligo(dT)25 magnetic beads (NE Biolabs) as described in
the Supplemental Information.
Mass Spectrometry, Protein Identification, and Quantification
Proteins were processed following standard protocols, and the resulting
peptides were fractionated and analyzed on a nano-HPLC system (Proxeon)
or nano-Acquity UPLC system (Waters) coupled directly to an LTQ Orbitrap
Velos (Thermo Fisher Scientific). A detailed description of the sample prepara-
tion, protein identification, and quantification can be found in the Supple-
mental Information.
GFP-Based Method for Detection of mRNA-Protein Interactions
HeLa cells expressing N- or C-terminally EGFP/YFP-tagged proteins (Table
S7) were induced with tetracycline, irradiated with UV light, and lysed. GFP-
binding protein (GBP; GFP agarose trap, Chromotek)-immunoprecipitated
mRNAs were detected using an oligo(dT)25 probe fused to TRed dye (Sigma).
RNAs coimmunoprecipitated with GFP/YFP-tagged proteins were identified
by RNASeq. Detailed protocols can be found in the Supplemental Information.
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Table 1. RNA-Binding Metabolic Enzymes
Protein Class Reactome Pathway Cofactor
ALDH18A1 mRNA interactome 13 amino acids and derivatives dinucleotide
PKM2 mRNA interactome 474 carbohydrates nucleotide and anionic substrate
ENO1 mRNA interactome 474 carbohydrates
LTA4H mRNA interactome 22258, 15369 lipids and lipoproteins;
prostanoid metabolism
ALDH6A1 mRNA interactome 13 amino acids and derivatives dinucleotide
DUT mRNA interactome 1698, 957 nucleotides; pyrimidine metabolism
ASS1 mRNA interactome 13 amino acids and derivatives nucleotide and anionic substrate
TXN mRNA interactome 1698 nucleotides
HADHB mRNA interactome 22279 fatty acids; triacylglycerol
and ketone body
dinucleotide
MDH2 mRNA interactome 1046 pyruvate and TCA dinucleotide
ADK mRNA interactome 1698, 522 nucleotides; purine nucleotide and anionic substrate
FDPS mRNA interactome 22258 lipids and lipoproteins
SUCLG1 mRNA interactome 1046 pyruvate and TCA cycle nucleotide and anionic substrate
FASN mRNA interactome 22279, 11193 fatty acids, ketone, vitamins,
and cofactors
dinucleotide
NQO1 mRNA interactome 13 amino acids and derivatives dinucleotide
P4HB mRNA interactome 22258 lipids and lipoproteins
NME1 mRNA interactome 1698 nucleotides nucleotide and anionic substrate
SHMT2 candidate RBP amino acid and folate
AK2 candidate RBP 1698 nucleotides nucleotide and anionic substrate
CPS1 candidate RBP 13 amino acids and derivatives nucleotide and anionic substrate
SDHA candidate RBP 1046 pyruvate and TCA cycle dinucleotide
CAD candidate RBP 1698, 957 nucleotides; pyrimidine
AKR1B1 candidate RBP 22258, 11057 lipids and lipoproteins; steroid
hormones, and vitamins A and D
dinucleotide
BLVRB candidate RBP 9431 porphyrins dinucleotide
DLD candidate RBP 13, 1046, 2071 amino acids and pyruvate; TCA cycle dinucleotide
MTHFD1 candidate RBP 11238, 11167, 11193 vitamins and cofactors;
folate and pterines
dinucleotide
GMPR2 candidate RBP 1698, 522 nucleotides; purine dinucleotide
PGK1 candidate RBP 723, 474 carbohydrates: glucose nucleotide and anionic substrate
DECR1 candidate RBP 22279, 22258 fatty acid, triacylglycerol,
and ketone body
dinucleotide
ENO3 candidate RBP 723, 474 carbohydrates; glucose
MVK candidate RBP 22258 lipids and lipoproteins nucleotide and anionic substrate
GAPDH candidate RBP 723, 474 carbohydrates; glucose dinucleotide
TPI1 candidate RBP 723, 474 carbohydrates; glucose
LDHB candidate RBP 1046, 2071 pyruvate and TCA cycle dinucleotide
KYNU candidate RBP 13 amino acids and derivatives
DHCR24 candidate RBP 22258 lipids and lipoproteins dinucleotide
CAT candidate RBP 1698, 522 nucleotides; purine
ACLY candidate RBP 1505, 22279, 22258 energy integration; fatty acid, triacylglicerol;
lipids and lipoproteins
nucleotide and anionic substrate
IDH1 candidate RBP 1046, 22258, 16957 lipids and lipoproteins;
pyruvate and TCA cycle
dinucleotide
HADH candidate RBP 22258, 22279 lipids and lipoproteins; fatty acid,
triacylglycerol, and ketone body
dinucleotide
ALDOA candidate RBP 723, 474 carbohydrates; glucose
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Table 1. Continued
Protein Class Reactome Pathway Cofactor
ALAS2 candidate RBP 9431 porphyrins
TKT candidate RBP 1505, 474 energy integration; carbohydrates
PGAM1 candidate RBP 723, 474 carbohydrates; glucose
GATM candidate RBP 13, 813 amino acids and derivatives; creatine
IDH2 candidate RBP 1046 pyruvate and TCA cycleR/Bioconductor data package mRNAinteractomeHeLa contains the R-scripts
used for the analysis in this manuscript (http://www.bioconductor.org). Distri-
bution of disordered and repetitive regions in HeLa RBPs can be found in
http://www.embl.de/mRNAinteractome.
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